Dio Tree

Dio tree email format

Verified email-pattern data for Dio Tree is currently limited. You can still use the company insights and contact sections below.
Ovarian cancer is a therapeutic challenge. Despite the existing treatments (chemotherapy, PARP inhibitors and VEGF inhibitors), most patients develop resistance and therefore the survival rates are extremely low. The global ovarian cancer patient market represents about 300 thousand patients per year. This market is also expected to grow by nearly 40 percent by 2040. The disease is considered an orphan drug and therefore the regulatory pathway at the FDA is fast and with leniencies in development. DIO3 is expressed at a high level in ovarian cancer high grade serous (HGSOC), an aggressive disease with extremely high mortality rates. The technology involved a series of small molecules, the first of their kind for specific inhibition of DIO3. Finally, the DIO3 enzyme is expressed in other aggressive tumors, including breast and lung cancer, and therefore the drugs have an even greater market potential.

Company Details

Employees
4
Founded
-
Address
Wadi Al-Haj, Nazareth,israel
Industry
Pharmaceutical Manufacturing
HQ
Nazareth
Looking for a particular Dio Tree employee's phone or email?

Dio Tree Questions

Explore related pages

Related company profiles:

Top Dio Tree Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant